{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:38:17Z","timestamp":1772825897064,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hlc.2020.01.017","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T08:08:10Z","timestamp":1583482090000},"page":"1459-1468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-1717","authenticated-orcid":false,"given":"James","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3002-0868","authenticated-orcid":false,"given":"Melanie","family":"Lavender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Celermajer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Horrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-6927","authenticated-orcid":false,"given":"Dominic","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Kotlyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Whitford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Strange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25 Suppl","key":"10.1016\/j.hlc.2020.01.017_bib1","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2020.01.017_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.hlc.2020.01.017_bib3","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.hlc.2017.08.018","article-title":"Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand","volume":"27","author":"Strange","year":"2018","journal-title":"Heart Lung Circ"},{"issue":"24","key":"10.1016\/j.hlc.2020.01.017_bib4","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1136\/heartjnl-2012-301992","article-title":"Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort","volume":"98","author":"Strange","year":"2012","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.hlc.2020.01.017_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1378\/chest.10-1166","article-title":"Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry","volume":"140","author":"Brown","year":"2011","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.hlc.2020.01.017_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2045-8932.109919","article-title":"Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study","volume":"3","author":"Strange","year":"2013","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.hlc.2020.01.017_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.chest.2016.08.1461","article-title":"Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis","volume":"151","author":"Jain","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.hlc.2020.01.017_bib8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A\u00a0meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"issue":"142","key":"10.1016\/j.hlc.2020.01.017_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1183\/16000617.0084-2016","article-title":"Future perspectives in pulmonary arterial hypertension","volume":"25","author":"Simonneau","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.hlc.2020.01.017_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachiery","year":"2018","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.hlc.2020.01.017_bib12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2020.01.017_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.09.043","article-title":"Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: a meta-analysis","volume":"273","author":"Cao","year":"2018","journal-title":"Int J Cardiol"},{"issue":"23","key":"10.1016\/j.hlc.2020.01.017_bib14","first-page":"2294","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"374","author":"Wright","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hlc.2020.01.017_bib15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hlc.2020.01.017_bib16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hlc.2020.01.017_bib17","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2020.01.017_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.hlc.2020.01.017_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.21693\/1933-088X-16.4.170","article-title":"Center-based care for pulmonary hypertension: a\u00a0European perspective","volume":"16","author":"Gibbs","year":"2018","journal-title":"Adv Pulm Hypertens"},{"issue":"2","key":"10.1016\/j.hlc.2020.01.017_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.hlc.2020.01.017_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Galie","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.hlc.2020.01.017_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2020.01.017_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.hlc.2020.01.017_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hlc.2020.01.017_bib25","author":"Rural and remote Australians"},{"key":"10.1016\/j.hlc.2020.01.017_bib26","series-title":"Pulmonary arterial hypertension designated centres","year":"2018"},{"issue":"4","key":"10.1016\/j.hlc.2020.01.017_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum","volume":"68","author":"Opitz","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2020.01.017_bib28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ijcard.2012.10.026","article-title":"Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry","volume":"168","author":"Hoeper","year":"2013","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2020.01.017_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1524-4733.2009.00568.x","article-title":"The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III","volume":"12","author":"Stevenson","year":"2009","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.hlc.2020.01.017_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-015-0366-8","article-title":"Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: a modelling study","volume":"34","author":"Coyle","year":"2016","journal-title":"Pharmacoeconomics"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950620300652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950620300652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:02:35Z","timestamp":1761415355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950620300652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1443950620300652"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2020.01.017","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2020.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). All rights reserved.","name":"copyright","label":"Copyright"}]}}